Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Novavax Inc's Business Segments
Novavax Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 140
Regions Reported
2
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 140 | 100% |
Revenue Share by Region - Q1 FY2026
- Rest of the world16.7%
- Europe14.4%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Rest of the world | $ 23 | 16.7% |
| Europe | $ 20 | 14.4% |
Revenue by Product & Service Category - Q1 FY2026
- Licensing, royalties, and other69.8%
- Product30.2%
- Supply sales23.4%
- Nuvaxovid sales6.9%
- Royalty2.5%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Licensing, royalties, and other | $ 97 | 69.8% |
| Product | $ 42 | 30.2% |
| Supply sales | $ 33 | 23.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
2 more categories available
Sign in to unlock the full Novavax Inc dataset.
Description of Novavax Inc
Novavax Inc.
is a clinical-stage biotechnology company that specializes in the development of vaccines to prevent infectious diseases.
The company is headquartered in Gaithersburg, Maryland, and was founded in 1987.
Novavax's focus is on developing novel recombinant protein nanoparticle vaccines using its proprietary technology platform, Matrix-M.
Matrix-M is a proprietary saponin adjuvant that stimulates the immune system and enhances the efficacy of vaccines.
Novavax has used this adjuvant to develop vaccines for a variety of infectious diseases, including influenza, respiratory syncytial virus (RSV), COVID-19, and Ebola.
Novavax's lead product candidate, NVX-CoV2373, is a COVID-19 vaccine that uses Matrix-M to enhance the immune response to the SARS-CoV-2 spike protein.
The vaccine is administered in two doses, 21 days apart, and has shown high levels of efficacy in clinical trials conducted in the UK and South Africa.
Novavax has partnered with several organizations to develop and distribute its vaccines globally.
In the US, the company has received funding from the US Department of Defense, the National Institutes of Health, and the Coalition for Epidemic Preparedness Innovations (CEPI).
Overall, Novavax Inc is a biotechnology company that is pioneering the use of recombinant protein nanoparticle vaccines, with its proprietary Matrix-M technology.
The company has a strong pipeline of vaccines and partnerships with several organizations for global distribution.
is a clinical-stage biotechnology company that specializes in the development of vaccines to prevent infectious diseases.
The company is headquartered in Gaithersburg, Maryland, and was founded in 1987.
Novavax's focus is on developing novel recombinant protein nanoparticle vaccines using its proprietary technology platform, Matrix-M.
Matrix-M is a proprietary saponin adjuvant that stimulates the immune system and enhances the efficacy of vaccines.
Novavax has used this adjuvant to develop vaccines for a variety of infectious diseases, including influenza, respiratory syncytial virus (RSV), COVID-19, and Ebola.
Novavax's lead product candidate, NVX-CoV2373, is a COVID-19 vaccine that uses Matrix-M to enhance the immune response to the SARS-CoV-2 spike protein.
The vaccine is administered in two doses, 21 days apart, and has shown high levels of efficacy in clinical trials conducted in the UK and South Africa.
Novavax has partnered with several organizations to develop and distribute its vaccines globally.
In the US, the company has received funding from the US Department of Defense, the National Institutes of Health, and the Coalition for Epidemic Preparedness Innovations (CEPI).
Overall, Novavax Inc is a biotechnology company that is pioneering the use of recombinant protein nanoparticle vaccines, with its proprietary Matrix-M technology.
The company has a strong pipeline of vaccines and partnerships with several organizations for global distribution.
Overview of Novavax Inc.
Novavax Inc. is a prominent biotech company that is committed to the development, production, and distribution of innovative vaccines aimed at combating infectious diseases. Utilizing cutting-edge technologies and scientific advancements, Novavax focuses on creating vaccines that enhance safety profiles and effectiveness compared to currently available options. The company emphasizes a robust pipeline of vaccine candidates targeting a variety of infectious diseases, demonstrating its dedication to global health and public safety.
Segments
Novavax operates primarily within a single segment dedicated to the development and production of vaccines for infectious diseases. This streamlined focus allows for specialized expertise and resource allocation toward creating effective immunization solutions. The company’s extensive product pipeline addresses various infectious diseases, including:
- Seasonal Influenza
- Respiratory Syncytial Virus (RSV)
- Ebola
- Middle East Respiratory Syndrome (MERS)
- COVID-19
This segmental concentration enables Novavax to leverage its advanced technological capabilities and maintain strategic partnerships to facilitate the rapid development of vaccines in response to emerging public health needs.
Products
1. COVID-19 Vaccine:
- Novavax’s COVID-19 vaccine employs a protein-based platform designed to elicit a robust immune response. The vaccine is administered in two doses, spaced 21 days apart, and has demonstrated significant efficacy in clinical trials. Following promising results, it has received emergency use authorization in numerous countries, marking its critical role in the global vaccination effort against COVID-19.
2. NanoFlu Vaccine:
- The NanoFlu vaccine is a recombinant influenza vaccine that incorporates Novavaxs proprietary Matrix-M adjuvant technology. This innovative approach enhances the immune response compared to traditional flu vaccines, aiming to provide broader and longer-lasting protection against seasonal influenza variants.
3. ResVax:
- Targeting respiratory syncytial virus (RSV), ResVax is designed to protect infants through maternal immunization. The vaccine has shown encouraging results in clinical trials, especially aimed at reducing severe RSV-related complications in vulnerable populations, including infants and older adults.
4. RSV F Vaccine:
- The RSV F vaccine focuses specifically on older adults, who are at heightened risk for severe RSV infection. Currently in Phase 3 clinical trials, this fusion protein-based vaccine aims to provide an effective preventive measure against RSV in this demographic, contributing to better health outcomes.
5. Ebola Vaccine:
- Novavax’s Ebola vaccine has demonstrated high efficacy in clinical trials and has achieved conditional approval for use in the European Union. This vaccine addresses the critical need for effective immunization strategies in response to outbreaks of the Ebola virus.
Services
In addition to its vaccine development, Novavax offers a variety of services that support the overarching goal of advancing public health through immunization:
1. Research and Development:
- Novavax prioritizes significant investment in research and development to innovate and improve its vaccine offerings. The company utilizes its proprietary technologies to create new candidates that address pressing infectious disease challenges.
2. Manufacturing:
- With a state-of-the-art manufacturing facility located in the Czech Republic, Novavax is capable of producing vaccines for both clinical trials and commercial distribution. This facility allows for scalable production methods that meet strict regulatory standards.
3. Clinical Trials:
- Novavax actively conducts clinical trials to rigorously evaluate the safety, tolerability, and efficacy of its vaccine candidates. These trials are crucial in gaining the necessary approvals and ensuring that their products meet the required therapeutic standards.
4. Regulatory Support:
- Navigating the complex regulatory landscape of vaccine development can be challenging. Novavax provides comprehensive regulatory support, helping to facilitate the approval process for its vaccine candidates in various jurisdictions.
5. Distribution:
- To ensure effective delivery of its vaccines, Novavax partners with governments, non-profits, and distribution networks. This collaborative approach is instrumental in making its vaccines accessible to populations in need, particularly in regions stricken by infectious diseases.
Conclusion
In summary, Novavax Inc. stands at the forefront of vaccine innovation, with a focused pipeline dedicated to combating major infectious diseases. Through its diversified product offerings, advanced research and development initiatives, and comprehensive support services, Novavax plays a vital role in enhancing global health and addressing urgent public health challenges.
Novavax Inc. is a prominent biotech company that is committed to the development, production, and distribution of innovative vaccines aimed at combating infectious diseases. Utilizing cutting-edge technologies and scientific advancements, Novavax focuses on creating vaccines that enhance safety profiles and effectiveness compared to currently available options. The company emphasizes a robust pipeline of vaccine candidates targeting a variety of infectious diseases, demonstrating its dedication to global health and public safety.
Segments
Novavax operates primarily within a single segment dedicated to the development and production of vaccines for infectious diseases. This streamlined focus allows for specialized expertise and resource allocation toward creating effective immunization solutions. The company’s extensive product pipeline addresses various infectious diseases, including:
- Seasonal Influenza
- Respiratory Syncytial Virus (RSV)
- Ebola
- Middle East Respiratory Syndrome (MERS)
- COVID-19
This segmental concentration enables Novavax to leverage its advanced technological capabilities and maintain strategic partnerships to facilitate the rapid development of vaccines in response to emerging public health needs.
Products
1. COVID-19 Vaccine:
- Novavax’s COVID-19 vaccine employs a protein-based platform designed to elicit a robust immune response. The vaccine is administered in two doses, spaced 21 days apart, and has demonstrated significant efficacy in clinical trials. Following promising results, it has received emergency use authorization in numerous countries, marking its critical role in the global vaccination effort against COVID-19.
2. NanoFlu Vaccine:
- The NanoFlu vaccine is a recombinant influenza vaccine that incorporates Novavaxs proprietary Matrix-M adjuvant technology. This innovative approach enhances the immune response compared to traditional flu vaccines, aiming to provide broader and longer-lasting protection against seasonal influenza variants.
3. ResVax:
- Targeting respiratory syncytial virus (RSV), ResVax is designed to protect infants through maternal immunization. The vaccine has shown encouraging results in clinical trials, especially aimed at reducing severe RSV-related complications in vulnerable populations, including infants and older adults.
4. RSV F Vaccine:
- The RSV F vaccine focuses specifically on older adults, who are at heightened risk for severe RSV infection. Currently in Phase 3 clinical trials, this fusion protein-based vaccine aims to provide an effective preventive measure against RSV in this demographic, contributing to better health outcomes.
5. Ebola Vaccine:
- Novavax’s Ebola vaccine has demonstrated high efficacy in clinical trials and has achieved conditional approval for use in the European Union. This vaccine addresses the critical need for effective immunization strategies in response to outbreaks of the Ebola virus.
Services
In addition to its vaccine development, Novavax offers a variety of services that support the overarching goal of advancing public health through immunization:
1. Research and Development:
- Novavax prioritizes significant investment in research and development to innovate and improve its vaccine offerings. The company utilizes its proprietary technologies to create new candidates that address pressing infectious disease challenges.
2. Manufacturing:
- With a state-of-the-art manufacturing facility located in the Czech Republic, Novavax is capable of producing vaccines for both clinical trials and commercial distribution. This facility allows for scalable production methods that meet strict regulatory standards.
3. Clinical Trials:
- Novavax actively conducts clinical trials to rigorously evaluate the safety, tolerability, and efficacy of its vaccine candidates. These trials are crucial in gaining the necessary approvals and ensuring that their products meet the required therapeutic standards.
4. Regulatory Support:
- Navigating the complex regulatory landscape of vaccine development can be challenging. Novavax provides comprehensive regulatory support, helping to facilitate the approval process for its vaccine candidates in various jurisdictions.
5. Distribution:
- To ensure effective delivery of its vaccines, Novavax partners with governments, non-profits, and distribution networks. This collaborative approach is instrumental in making its vaccines accessible to populations in need, particularly in regions stricken by infectious diseases.
Conclusion
In summary, Novavax Inc. stands at the forefront of vaccine innovation, with a focused pipeline dedicated to combating major infectious diseases. Through its diversified product offerings, advanced research and development initiatives, and comprehensive support services, Novavax plays a vital role in enhancing global health and addressing urgent public health challenges.